Karyopharm Therapeutics Inc. (KPTI): Price and Financial Metrics

Karyopharm Therapeutics Inc. (KPTI): $6.31

0.20 (+3.27%)

POWR Rating

Component Grades














  • KPTI scores best on the Value dimension, with a Value rank ahead of 71.65% of US stocks.
  • The strongest trend for KPTI is in Momentum, which has been heading down over the past 48 weeks.
  • KPTI ranks lowest in Stability; there it ranks in the 2nd percentile.

KPTI Stock Summary

  • Karyopharm Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 3.79% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 105 for Karyopharm Therapeutics Inc; that's greater than it is for 99.67% of US stocks.
  • In terms of volatility of its share price, KPTI is more volatile than 93.05% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Karyopharm Therapeutics Inc are AERI, SESN, APLS, EXTR, and PBYI.
  • Visit KPTI's SEC page to see the company's official filings. To visit the company's web site, go to www.karyopharm.com.

KPTI Valuation Summary

  • In comparison to the median Healthcare stock, KPTI's EV/EBIT ratio is 108.87% lower, now standing at -2.6.
  • KPTI's EV/EBIT ratio has moved up 18.3 over the prior 95 months.
  • Over the past 95 months, KPTI's price/sales ratio has gone down 1018.6.

Below are key valuation metrics over time for KPTI.

Stock Date P/S P/B P/E EV/EBIT
KPTI 2021-08-31 4.3 -5.3 -2.1 -2.6
KPTI 2021-08-30 4.0 -5.0 -2.0 -2.5
KPTI 2021-08-27 4.1 -5.1 -2.0 -2.5
KPTI 2021-08-26 3.8 -4.6 -1.9 -2.3
KPTI 2021-08-25 3.8 -4.7 -1.9 -2.4
KPTI 2021-08-24 3.7 -4.6 -1.8 -2.3

KPTI Growth Metrics

  • Its 2 year price growth rate is now at 15.4%.
  • Its 3 year net income to common stockholders growth rate is now at -72.95%.
  • Its 5 year cash and equivalents growth rate is now at 363.69%.
KPTI's revenue has moved up $102,054,000 over the prior 70 months.

The table below shows KPTI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 102.294 -183.582 -207.912
2021-03-31 113.207 -168.111 -200.756
2020-12-31 108.085 -160.234 -196.273
2020-09-30 91.081 -169.089 -201.499
2020-06-30 82.897 -161.283 -189.371
2020-03-31 58.876 -169.21 -186.36

KPTI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • KPTI has a Quality Grade of C, ranking ahead of 58.23% of graded US stocks.
  • KPTI's asset turnover comes in at 0.338 -- ranking 136th of 677 Pharmaceutical Products stocks.
  • CAPR, DRNA, and PLXP are the stocks whose asset turnover ratios are most correlated with KPTI.

The table below shows KPTI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.338 0.965 -0.614
2021-03-31 0.347 0.975 -0.545
2020-12-31 0.299 0.975 -0.534
2020-09-30 0.255 0.967 -0.576
2020-06-30 0.239 0.956 -0.607
2020-03-31 0.189 0.945 -0.671

KPTI Price Target

For more insight on analysts targets of KPTI, see our KPTI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.22 Average Broker Recommendation 1.6 (Moderate Buy)

KPTI Stock Price Chart Interactive Chart >

Price chart for KPTI

KPTI Price/Volume Stats

Current price $6.31 52-week high $18.00
Prev. close $6.11 52-week low $4.42
Day low $5.88 Volume 1,006,778
Day high $6.31 Avg. volume 1,956,691
50-day MA $6.46 Dividend yield N/A
200-day MA $10.72 Market Cap 476.39M

Karyopharm Therapeutics Inc. (KPTI) Company Bio

Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company was founded in 2008 and is based in in Newton, Massachusetts.

KPTI Latest News Stream

Event/Time News Detail
Loading, please wait...

KPTI Latest Social Stream

Loading social stream, please wait...

View Full KPTI Social Stream

Latest KPTI News From Around the Web

Below are the latest news stories about Karyopharm Therapeutics Inc that investors may wish to consider to help them evaluate KPTI as an investment opportunity.

Karyopharm Announces Upcoming Virtual Investor Conference Participation

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer, will participate in the following virtual investor conferences in September:

Yahoo | September 7, 2021

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that in connection with the hiring of Eleonora Goldberg, Senior Vice President of Global Medical & Scientific Affairs, the Compensation Committee of Karyopharm's Board of Directors granted a stock option to purchase 100,000 shares of Karyopharm's common stock to Dr. Goldberg, with a grant date of August 31, 2021. The stock option was granted as an inducement m

Yahoo | September 1, 2021

Global Pet Cancer Therapeutics Market Size, Trends and Forecast 2027 By | Karyopharm Therapeutics, Inc., Zoetis

The Pet Cancer Therapeutics Market study provides a thorough but completes analysis of the worldwide Pet Cancer Therapeutics market, including all of the major company profiles that have an impact on the market''s growth and breadth. The study is written

OpenPR | August 24, 2021

Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock Options

Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.

Yahoo | August 20, 2021

Cramer Shares His Thoughts On Moderna, Nvidia And More

On CNBC''s "Mad Money Lightning Round," Jim Cramer said Karyopharm Therapeutics Inc (NASDAQ: KPTI ) is nothing special. Cramer likes Iron Mountain Inc (NYSE: IRM ).

Business Insider Markets | August 13, 2021

Read More 'KPTI' Stories Here

KPTI Price Returns

1-mo 24.70%
3-mo -42.58%
6-mo -38.74%
1-year -57.65%
3-year -65.44%
5-year -32.51%
YTD -59.24%
2020 -19.25%
2019 104.59%
2018 -2.40%
2017 2.13%
2016 -29.06%

Continue Researching KPTI

Want to see what other sources are saying about Karyopharm Therapeutics Inc's financials and stock price? Try the links below:

Karyopharm Therapeutics Inc (KPTI) Stock Price | Nasdaq
Karyopharm Therapeutics Inc (KPTI) Stock Quote, History and News - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9643 seconds.